ALNYLAM
"ALNYLAM" is a word mark owned by Alnylam Pharmaceuticals, Inc., filed at IP Australia on July 24, 2018. It is registered and covers class 5 (Pharmaceuticals).
- Status
- Registered
- Since December 18, 2018
- Filed
- July 24, 2018
- Registered
- July 24, 2018
- Expires
- July 24, 2028
- Application no.
- 1943207
- Registration no.
- 1943207
- Office
- IP Australia
- IP Australia
- Mark type
- Word mark
- 1 class
Who owns ALNYLAM
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Alnylam Pharmaceuticals, Inc.
ALNY · United States
Representative
Corrs Chambers Westgarth
Corrs Chambers Westgarth
What the mark covers
The products and services ALNYLAM is filed for, grouped by Nice class.
Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceutical preparations, namely, RNA therapeutics; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes
What has happened so far
Steps recorded by IP Australia, newest first.
- IP Right Registered correspondence sent
- IP Right Acceptance Published
- Amend Status from Awaiting Advertisement
- Application Accepted correspondence sent
- IP Right Filed Published
- Application Status
- Application Status
- Status change to Filed
- Filing an Electronic Application for a TM 1 Class
About ALNYLAM
Who owns the trademark "ALNYLAM"?
IP Australia trademark "ALNYLAM" (application 1943207) is owned by Alnylam Pharmaceuticals, Inc.
What is the status of "ALNYLAM"?
Its status at IP Australia is: registered.
When was "ALNYLAM" registered?
It was registered on July 24, 2018 and is due to expire on July 24, 2028.
Get this data via the API
Everything on this page comes from the Signa API. Pull ALNYLAM and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019dfc3a-8a2c-71c1-9ffb-254ae5617c1c
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019dfc3a-8a2c-71c1-9ffb-254ae5617c1c",
"object": "trademark",
"mark_text": "ALNYLAM",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "AU",
"application_number": "1943207",
"filing_date": "2018-07-24",
"nice_classes": [
5
],
"owners": [
{
"name": "Alnylam Pharmaceuticals, Inc.",
"entity_id": "ent_019eb709-7d9a-70dc-b19d-2c56e8a223b5"
}
]
}